Currently, Quizartinib is being evaluated in a phase 1/2 study both in combination with re-induction chemotherapy and as a single-agent maintenance therapy in relapsed/refractory pediatric AML with FLT3-ITD mutations (NCT03793478). The gene discussed is FLT3; the disease is acute myeloid leukemia.